The Government of Canada has recently announced major investments in Canadian firms, including a $32.7 million contribution to Septodont’s division in Cambridge, Ontario. This investment will support a significant project to increase Canada’s biomanufacturing capacity for fill-finish of sterile injectables in a state-of-the-art GMP facility expansion.
“Such a proud moment for Septodont. By creating such capacity and capabilities, Novocol will contribute to strengthening Canada’s preparedness for future pandemics, as well as create skilled jobs and economic development in the country’s biopharmaceutical ecosystem. This is also an important step in our diversification strategy that will allow us to continue to expand our reach beyond dental, using our core competencies in injectable manufacturing.”
Olivier Schiller
CEO of Novocol Pharma’s French-based parent company, Septodont
Sign up for Oral Health Group’s weekly e-newsletter to have news delivered straight to your inbox!
